# Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct04120623` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04120623](<https://clinicaltrials.gov/study/NCT04120623>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04120623

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04120623. Randomized; single masking; primary purpose treatment. Start 2019-10-01 (anticipated); primary completion 2019-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04120623, source copy `cardio:ctgov-nct04120623-2019-10-09`, retrieved 2026-10-26)
- Planned start: 2019-10-01 (anticipated) (ClinicalTrials.gov record NCT04120623, source copy `cardio:ctgov-nct04120623-2019-10-09`, retrieved 2026-10-26)
- Primary completion: 2019-12-31 (anticipated) (ClinicalTrials.gov record NCT04120623, source copy `cardio:ctgov-nct04120623-2019-10-09`, retrieved 2026-10-26)
- Completion: 2020-02-28 (anticipated) (ClinicalTrials.gov record NCT04120623, source copy `cardio:ctgov-nct04120623-2019-10-09`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04120623-2019-10-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dapagliflozin 10 MG
- Intervention (Drug): Insulin Aspart
- Lead sponsor: Nanjing First Hospital, Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Nanjing First Hospital, Nanjing Medical University (`cardio:org-nanjing-first-hospital-nanjing-medical-university`)

## Provenance

Content hash: 09bf8424bed6252d0f76fd54222fa6a162f3f2c9849821d43fbda18a0c188a56
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
